The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected
to provide more favorable bioavailability characteristics than the present commercial
formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.